Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Business Wire•02/11/2026•18:05 ET
2
Key Highlights
- ➤Agenus executives will discuss botensilimab and balstilimab development November 5, 2026
- ➤Discussion includes neoadjuvant colon cancer results from NEST, UNICORN and NEOASIS
- ➤Management will discuss planned Phase 3 ROBBIN trial
- ➤Management will address strategic priorities, funding and BOT+BAL commercial opportunity
Expert Statements
Robin Taylor, Chief Commercial Officer of Agenus
“Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat”
Zack Armen, Vice President of Corporate Development and Investor Relations of Agenus
“Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat”
Michael G. King, Jr., Senior Biotechnology Analyst at Rodman & Renshaw
“Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat”
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday, November 5, 2026.
Get started
Create a free account to read the full story.